Christopher J. Calamari - Jul 1, 2021 Form 3 Insider Report for ABBOTT LABORATORIES (ABT)

Role: SENIOR VICE PRESIDENT
Signature: /s/ Christopher J. Calamari by Jessica H. Paik, Attorney-in-Fact
Stock symbol: ABT
Transactions as of: Jul 1, 2021
Transactions value $: $0
Form type: 3
Date filed: 7/6/2021, 05:03 PM
Next filing: Feb 23, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABT	Common shares without par value						12.2K	Jul 1, 2021	Direct
holding	ABT	Common shares without par value						30.2K	Jul 1, 2021	The Calamari Family Trust
holding	ABT	Common shares without par value						100	Jul 1, 2021	Profit Sharing Trust	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ABT	Option (right to buy)							Jul 1, 2021	Common Shares	51.6K	$59.94	Direct	F2
holding	ABT	Option (right to buy)							Jul 1, 2021	Common Shares	42K	$75.90	Direct	F3
holding	ABT	Option (right to buy)							Jul 1, 2021	Common Shares	37.1K	$87.72	Direct	F4
holding	ABT	Option (right to buy)							Jul 1, 2021	Common Shares	27.8K	$124.04	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Balance in the Abbott Laboratories Stock Retirement Trust as of July 1, 2021.
F2	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 17,187 on February 16, 2019, 17,187 on February 16, 2020 and 17,186 on February 16, 2021.
F3	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 14,003 on February 22, 2020 and 14,003 on February 22, 2021, and an increment of 14,003 becomes exercisable on February 22, 2022.
F4	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 12,360 on February 21, 2021 and annual increments of 12,360 and 12,361 become exercisable on February 21, 2022 and February 21, 2023, respectively.
F5	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,280 on February 19, 2022, 9,280 on February 19, 2023, and 9,280 on February 19, 2024.